Josh Resnick, MD is a Managing Director at RA Capital Management. Josh’s primary responsibility at RA Capital is to lead early-stage private investments and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. He has more than 15 years of experience in investing, company formation, and company leadership across all […]
Team Role: Board
Matthew R. Patterson
Matt Patterson is a biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company’s inception in November 2012 until its acquisition […]
Kush M. Parmar, MD, PhD
Kush M. Parmar, MD, PhD is a managing partner at 5AM Ventures. Kush serves as a Director on the Boards of Akouos (NASDAQ: AKUS), Ensoma, Entrada (NASDAQ: TRADA), GlycoEra, Homology (NASDAQ: FIXX), and Rallybio. He previously served as acting Vice President of Strategy and Corporate Development at Novira (acquired by J&J) and served as Board […]
Bill Lundberg, MD
Bill Lundberg, MD is a medical oncologist with more than two decades of experience managing and leading biotechnology research and development. Bill is President and CEO at Merus, a clinical-stage oncology company developing innovative, full-length multispecific antibodies. Prior to joining Merus, he served as Chief Scientific Officer at CRISPR Therapeutics, where he was responsible for […]
David Lubner
David Lubner is a senior finance executive with more than 25 years of experience in the life sciences industry. David served as Executive Vice President and Chief Financial Officer of Ra Pharma until May 2020 following its acquisition by UCB. Prior to Ra Pharma, he was Senior Vice President and Chief Financial Officer of Tetraphase […]
Daniella Beckman
Daniella Beckman has deep financial and operational experience across the biotechnology industry, having worked with both private and publicly traded companies throughout her career. At Tango Therapeutics, Daniella oversees finance, investor relations, and business development. Prior to joining Tango, she was a consultant to early-stage biotechnology companies, leading financial activities and building companies’ financial infrastructures. […]
Robert Ang, President and CEO
Robert Ang, MBBS, MBA brings experience as a senior biotech executive and is formerly a physician, venture capitalist, and strategy consultant. Prior to Vor Bio, Robert was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company prior to its Series A investment through IPO. Before Neon, he […]